AstraZeneca PLC (NYSE:AZN)

47.59
Delayed Data
As of Feb 24
 -2.58 / -5.14%
Today’s Change
36.83
Today|||52-Week Range
51.55
-4.55%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Major
MARKET CAP
$131.7B

Company Description

AstraZeneca Plc is a holding company, which engages in the research, development and manufacturing of pharmaceutical products. The company produces and commercializes medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology, and infectious diseases. Its pipeline consists of azd 4831, azd 8601, medi 6012, tagrisso bloom, durvalumab, selumetinib, lyparza polo, epanova, farxiga and brilinta. The company distributes its products under the following brands: Atacand, Crestor, Onglyza, Nexium, Entocort, Losec, Merrem/Meronem, Carbocaine, Citanest, Diprivan, Marcaine/Sensorcaine. AstraZeneca was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Contact Information

AstraZeneca Plc
Cambridge Biomedical Campus
Cambridge Cambridgeshire CB2 0AA
P:442037495000
Investor Relations:
442076048199

Employees

Shareholders

Other institutional6.14%
Mutual fund holders11.20%
Individual stakeholders--

Top Executives

There are no executives to display.